BIOLASE, Inc. (NASDAQ: BIOL) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $0.40 price target on the stock.
HighReport
BIOLASE, Inc. (NASDAQ: BIOL) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $0.40 price target on the stock.
BIOLASE, Inc. (NASDAQ: BIOL) had its price target lowered by analysts at Ascendiant Capital Markets from $3.50 to $2.00. They now have a "buy" rating on the stock.
LowReport
BIOLASE, Inc. (NASDAQ: BIOL) had its price target lowered by analysts at Ascendiant Capital Markets from $3.50 to $2.00. They now have a "buy" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: